Literature DB >> 22133090

Effect of persistent patent ductus arteriosus on mortality and morbidity in very low-birthweight infants.

Laurent Tauzin1, Corinne Joubert, Anne-Claire Noel, Antoine Bouissou, Marie-Eve Moulies.   

Abstract

AIM: Because New Caledonia is geographically isolated from the nearest cardiac surgical centre, surgical closure of ductus arteriosus is not performed in very low-birthweight (VLBW) infants who have a persistent patent ductus in spite of having undergone treatment with ibuprofen. This study aimed at investigating the possible effect of persistent patent ductus in VLBW infants.
METHODS: The study included 177 VLBW infants born at 25-31 weeks of gestation from January 2006 to May 2011. Mortality and major morbidities were compared between infants with a persistent patent ductus (n = 33) and those without it (n = 104). Statistical associations between potential neonatal risk factors and significant morbidities were identified using multivariate regression analyses.
RESULTS: Rates of mortality and major morbidities, including the rate of bronchopulmonary dysplasia, necrotizing enterocolitis, intraventricular haemorrhage grades I-II and III-IV, periventricular leucomalacia, late-onset infections and failure of hearing screening, were insignificantly higher in VLBW infants with a persistent patent ductus than in those without it.
CONCLUSION: This study adds further evidence that persistent patent ductus arteriosus has no significant effect on mortality and morbidity in VLBW infants born at ≥25 weeks' gestational age.
© 2011 The Author(s)/Acta Paediatrica © 2011 Foundation Acta Paediatrica.

Entities:  

Mesh:

Year:  2012        PMID: 22133090     DOI: 10.1111/j.1651-2227.2011.02550.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Risk factors associated with post-hemorrhagic hydrocephalus among very low birth weight infants of 24-28 weeks gestation.

Authors:  G Klinger; M Osovsky; V Boyko; N Sokolover; L Sirota; L Lerner-Geva; B Reichman
Journal:  J Perinatol       Date:  2016-03-03       Impact factor: 2.521

2.  Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus.

Authors:  N Margreth van der Lugt; Enrico Lopriore; Regina Bökenkamp; Vivianne E H J Smits-Wintjens; Sylke J Steggerda; Frans J Walther
Journal:  Eur J Pediatr       Date:  2012-08-05       Impact factor: 3.183

Review 3.  Patent ductus arteriosus in preterm infants: do we have the right answers?

Authors:  Hesham Abdel-Hady; Nehad Nasef; Abd Elazeez Shabaan; Islam Nour
Journal:  Biomed Res Int       Date:  2013-12-23       Impact factor: 3.411

4.  Development of a Diagnostic Clinical Score for Hemodynamically Significant Patent Ductus Arteriosus.

Authors:  Annemarie Kindler; Barbara Seipolt; Antje Heilmann; Ursula Range; Mario Rüdiger; Sigrun Ruth Hofmann
Journal:  Front Pediatr       Date:  2017-12-22       Impact factor: 3.418

Review 5.  Echocardiographic Evaluation of Patent Ductus Arteriosus in Preterm Infants.

Authors:  Romaine Arlettaz
Journal:  Front Pediatr       Date:  2017-06-21       Impact factor: 3.418

6.  Length at birth z-score is inversely associated with an increased risk of bronchopulmonary dysplasia or death in preterm infants born before 32 gestational weeks: A nationwide cohort study.

Authors:  Young Hwa Jung; Youngmi Park; Beyong Il Kim; Chang Won Choi
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

7.  Persistent Ductus Arteriosus in Critically Ill Preterm Infants.

Authors:  Maria Livia Ognean; Oana Boantă; Simona Kovacs; Corina Zgârcea; Raluca Dumitra; Ecaterina Olariu; Doina Andreicuţ
Journal:  J Crit Care Med (Targu Mures)       Date:  2016-11-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.